Literature DB >> 15841167

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Ellen J Kim1, Stephen Hess, Stephen K Richardson, Sara Newton, Louise C Showe, Bernice M Benoit, Ravi Ubriani, Carmela C Vittorio, Jacqueline M Junkins-Hopkins, Maria Wysocka, Alain H Rook.   

Abstract

Cutaneous T cell lymphomas (CTCLs) are a heterogenous group of lymphoproliferative disorders caused by clonally derived, skin-invasive T cells. Mycosis fungoides (MF) and Sezary syndrome (SS) are the most common types of CTCLs and are characterized by malignant CD4(+)/CLA(+)/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26. As MF/SS advances, the clonal dominance of the malignant cells results in the expression of predominantly Th2 cytokines, progressive immune dysregulation in patients, and further tumor cell growth. This review summarizes recent insights into the pathogenesis and immunobiology of MF/SS and how these have shaped current therapeutic approaches, in particular the growing emphasis on enhancement of host antitumor immune responses as the key to successful therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15841167      PMCID: PMC1070436          DOI: 10.1172/JCI24826

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  121 in total

1.  Imiquimod: a topically applied link between innate and acquired immunity.

Authors:  Daniel J Hurwitz; Laura Pincus; Thomas S Kupper
Journal:  Arch Dermatol       Date:  2003-10

2.  The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity.

Authors:  Satoshi Watanabe; Hiroshi Kagamu; Hirohisa Yoshizawa; Nanae Fujita; Hiroshi Tanaka; Junta Tanaka; Fumitake Gejyo
Journal:  J Immunol       Date:  2003-12-01       Impact factor: 5.422

Review 3.  Topical carmustine (BCNU) in the treatment of mycosis fungoides.

Authors:  Herschel S Zackheim
Journal:  Dermatol Ther       Date:  2003       Impact factor: 2.851

Review 4.  Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma.

Authors:  Chunlei Zhang; Madeleine Duvic
Journal:  Dermatol Ther       Date:  2003       Impact factor: 2.851

5.  Improved sensitivity of T-cell clonality detection in mycosis fungoides by hand microdissection and heteroduplex analysis.

Authors:  Olivier Dereure; Edi Levi; Eric C Vonderheid; Marshall E Kadin
Journal:  Arch Dermatol       Date:  2003-12

6.  CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.

Authors:  J Lundin; A Osterborg; G Brittinger; D Crowther; H Dombret; A Engert; A Epenetos; C Gisselbrecht; D Huhn; U Jaeger; J Thomas; R Marcus; N Nissen; C Poynton; E Rankin; R Stahel; M Uppenkamp; R Willemze; H Mellstedt
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

7.  Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides.

Authors:  Julia J Scarisbrick; Tracey J Mitchell; Eduardo Calonje; Guy Orchard; Robin Russell-Jones; Sean J Whittaker
Journal:  J Invest Dermatol       Date:  2003-10       Impact factor: 8.551

8.  Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma.

Authors:  Nikhil Yawalkar; Katalin Ferenczi; David A Jones; Keiichi Yamanaka; Ki-Young Suh; Sarah Sadat; Thomas S Kupper
Journal:  Blood       Date:  2003-06-26       Impact factor: 22.113

9.  Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity.

Authors:  Anke S Lonsdorf; Haydar Kuekrek; Britta V Stern; Bernhard O Boehm; Paul V Lehmann; Magdalena Tary-Lehmann
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

10.  Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma.

Authors:  Laszlo Kari; Andrey Loboda; Michael Nebozhyn; Alain H Rook; Eric C Vonderheid; Calen Nichols; Dezso Virok; Celia Chang; Wen-Hwai Horng; James Johnston; Maria Wysocka; Michael K Showe; Louise C Showe
Journal:  J Exp Med       Date:  2003-06-02       Impact factor: 14.307

View more
  94 in total

Review 1.  Tissue-specific homing of immune cells in malignant skin tumors.

Authors:  Hajnalka Jókai; Márta Marschalkó; Judit Csomor; József Szakonyi; Orsolya Kontár; Gábor Barna; Sarolta Kárpáti; Péter Holló
Journal:  Pathol Oncol Res       Date:  2012-04-24       Impact factor: 3.201

2.  Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors.

Authors:  James J Campbell; Rachael A Clark; Rei Watanabe; Thomas S Kupper
Journal:  Blood       Date:  2010-05-18       Impact factor: 22.113

3.  Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma.

Authors:  Kei-ichi Yamanaka; Robert C Fuhlbrigge; Hitoshi Mizutani; Thomas S Kupper
Journal:  Arch Dermatol Res       Date:  2010-01-29       Impact factor: 3.017

4.  A novel targeted immunotherapy for CTCL is on its way: Anti-KIR3DL2 mAb IPH4102 is potent and safe in non-clinical studies.

Authors:  Hélène Sicard; Cécile Bonnafous; Ariane Morel; Martine Bagot; Armand Bensussan; Anne Marie-Cardine
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

5.  Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.

Authors:  Alain H Rook; Joel M Gelfand; Joel C Gelfand; Maria Wysocka; Andrea B Troxel; Bernice Benoit; Christian Surber; Rosalie Elenitsas; Marie A Buchanan; Deborah S Leahy; Rei Watanabe; Ilan R Kirsch; Ellen J Kim; Rachael A Clark
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

6.  Risk of bacteremia in patients with cutaneous T-cell lymphoma (CTCL).

Authors:  Pamela B Allen; Jeffrey Switchenko; Amy Ayers; Esther Kim; Mary Jo Lechowicz
Journal:  Leuk Lymphoma       Date:  2020-06-19

7.  Clonotypic heterogeneity in cutaneous T-cell lymphoma (mycosis fungoides) revealed by comprehensive whole-exome sequencing.

Authors:  Aishwarya Iyer; Dylan Hennessey; Sandra O'Keefe; Jordan Patterson; Weiwei Wang; Thomas Salopek; Gane Ka-Shu Wong; Robert Gniadecki
Journal:  Blood Adv       Date:  2019-04-09

8.  Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins.

Authors:  Anders Woetmann; Paola Lovato; Karsten W Eriksen; Thorbjørn Krejsgaard; Tord Labuda; Qian Zhang; Anne-Merethe Mathiesen; Carsten Geisler; Arne Svejgaard; Mariusz A Wasik; Niels Ødum
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

9.  Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides: A Surveillance, Epidemiology, and End Results analysis.

Authors:  Amrita Goyal; Daniel O'Leary; Kavita Goyal; Nathan Rubin; Kimberly Bohjanen; Maria Hordinsky; Steven T Chen; Georgios Pongas; Lyn M Duncan; Aleksandr Lazaryan
Journal:  J Am Acad Dermatol       Date:  2019-07-30       Impact factor: 11.527

10.  Expression of T-plastin, FoxP3 and other tumor-associated markers by leukemic T-cells of cutaneous T-cell lymphoma.

Authors:  Elisabetta Capriotti; Eric C Vonderheid; Christopher J Thoburn; Mariusz A Wasik; David W Bahler; Allan D Hess
Journal:  Leuk Lymphoma       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.